// App-Quantinova.ai

7025 : Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) + ponatinib vs. HCVAD + dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Researchers

Presenter

  • Koji Sasaki

Principal Investigators

  • Hagop M. Kantarjian

  • Farhad Ravandi

  • Deborah A. Thomas

  • Naval Guastad Daver

  • Tapan M. Kadia

  • Marina Konopleva

  • Nitin Jain

  • Nicholas James Short

  • Ghayas C. Issa

  • Vicky Jeanis

  • H. Gal Moore

  • Rebecca S. Garris

  • Guillermo Garcia-Manero

  • Jorge E. Cortes

  • Susan Mary O'Brien

  • Elias Jabbour

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of California, Irvine, Fullerton, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Acute lymphoblastic leukemia

  • Hypercarotenemia and vitamin A deficiency

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Ponatinib

  • dasatinib

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • II

Study Id's

  • NCT01424982

  • NCT00390793

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved